It is imperative to study CD137L signalling in SLE, with an aim to garner a better understanding regarding how the CD137-CD137L co-stimulation system works in SLE before proceeding to the next step of investigating the clinical safety and therapeutic efficacy of manipulating the CD137-CD137L system in patients with SLE. This evidence concerns the gene TNFSF9 and systemic lupus erythematosus.